Advantages and limitations of amino acid PET for tracking therapy response in glioma patients

References

• Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315–e29.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Langen KJ. Applications of PET imaging of neurological tumors with radiolabeled amino acids. Q J Nucl Med Mol Imaging. 2015;59:70–82.
   PubMed Web of Science ®Google Scholar
• Langen KJ, Galldiks N, Hattingen E, et al. Advances in neuro-oncology imaging. Nat Rev Neurol. 2017;13(5):279–289.
   PubMed Web of Science ®Google Scholar
• Albert NL, Weller M, Suchorska B, et al. Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18:1199–1208.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Stoffels G, Filss C, et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. 2015;17:1293–1300.
   PubMed Web of Science ®Google Scholar
• Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540–557.
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–1280.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–1972.
   PubMed Web of Science ®Google Scholar
• Ahluwalia MS, Wen PY. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. Expert Rev Anticancer Ther. 2011;11:653–656.
   PubMed Web of Science ®Google Scholar
• FG D, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906–920.
   PubMed Web of Science ®Google Scholar
• Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113:405–410.
   PubMed Web of Science ®Google Scholar
• Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–2197.
   PubMed Web of Science ®Google Scholar
• Brandsma D.van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22:633–638.
   PubMed Web of Science ®Google Scholar
• Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–461.
   PubMed Web of Science ®Google Scholar
• Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16:e534–e42.
   PubMedGoogle Scholar
• Preusser M, Lim M, Hafler DA, et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;11:504–514.
   PubMed Web of Science ®Google Scholar
• JD W, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–4729.
   PubMed Web of Science ®Google Scholar
• Herholz K. Brain tumors: an update on clinical PET research in gliomas. Seminars in nuclear medicine. 2017;47:5–17.
   Google Scholar
• Chugani DC, Muzik O, Chakraborty P, et al. Human brain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl-L-tryptophan. Synapse. 1998;28:33–43.
   PubMed Web of Science ®Google Scholar
• Langen KJ, Galldiks N. Update on amino acid PET of brain tumors. Curr Opin Neurol. 2018;31:354–361.
   PubMed Web of Science ®Google Scholar
• Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205–212.
   PubMed Web of Science ®Google Scholar
• Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002;57:853–856.
   PubMed Web of Science ®Google Scholar
• Heiss WD, Wienhard K, Wagner R, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37:1180–1182.
   PubMed Web of Science ®Google Scholar
• Inoue T, Shibasaki T, Oriuchi N, et al. 18F alpha-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40:399–405.
   PubMed Web of Science ®Google Scholar
• Shoup TM, Olson J, Hoffman JM, et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331–338.
   PubMed Web of Science ®Google Scholar
• Approvals SODDa. Fluciclovine. US food & drug administration website. 2015. Available from: https://www.fda.gov/drugs
   Google Scholar
• Swissmedic. Swiss agency for therapeutic products. J Swissmedic. 2014;13:651.
   Google Scholar
• Langen KJ, Tonn JC, Weller M, et al. Letter to the editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435-460]. J Neurooncol. 2014;120:665–666.
   PubMed Web of Science ®Google Scholar
• Okubo S, Zhen HN, Kawai N, et al. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol. 2010;99:217–225.
   PubMed Web of Science ®Google Scholar
• Youland RS, Kitange GJ, Peterson TE, et al. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol. 2013;111:11–18.
   PubMed Web of Science ®Google Scholar
• Habermeier A, Graf J, Sandhofer BF, et al. System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids. 2015;47:335–344.
   PubMed Web of Science ®Google Scholar
• Becherer A, Karanikas G, Szabo M, et al. Brain tumor imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561–1567.
   PubMed Web of Science ®Google Scholar
• Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2- [(18)F]Fluoroethyl)-L-Tyrosine (FET)- and L-[Methyl-(11)C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049–1058.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Combs SE, Leotta K, et al. Intra-individual comparison of (18)F-FET and (18)F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol. 2014;16:434–440.
   PubMed Web of Science ®Google Scholar
• Calcagni ML, Galli G, Giordano A, et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med. 2011;36:841–847.
   PubMed Web of Science ®Google Scholar
• Popperl G, Kreth FW, Herms J, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. 2006;47:393–403.
   PubMed Web of Science ®Google Scholar
• Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:422–429.
   PubMed Web of Science ®Google Scholar
• Ginet M, Zaragori T, Marie PY, et al. Integration of dynamic parameters in the analysis of (18)F-FDopa PET imaging improves the prediction of molecular features of gliomas. Eur J Nucl Med Mol Imaging. 2019 Sep 16 Epub ahead of print. DOI:10.1007/s00259-019-04509-y.
   PubMed Web of Science ®Google Scholar
• Cicone F, Filss CP, Minniti G, et al. Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. Eur J Nucl Med Mol Imaging. 2015;42:905–915.
   PubMed Web of Science ®Google Scholar
• Forsting M, Albert FK, Kunze S, et al. Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. AJNR Am J Neuroradiol. 1993;14:77–87.
   PubMed Web of Science ®Google Scholar
• Scott JN, Brasher PM, Sevick RJ, et al. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947–949.
   PubMed Web of Science ®Google Scholar
• Lohmann P, Stavrinou P, Lipke K, et al. FET PET reveals considerable spatial differences in tumor burden compared to conventional MRI in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2019;46:591–602.
   PubMed Web of Science ®Google Scholar
• Pirotte B, Levivier M, Morelli D, et al. Positron emission tomography for the early postsurgical evaluation of pediatric brain tumors. Child’s Nerv Syst. 2005;21:294–300.
   PubMed Web of Science ®Google Scholar
• Pirotte BJ, Levivier M, Goldman S, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009;64:471–481.
   PubMed Web of Science ®Google Scholar
• Buchmann N, Klasner B, Gempt J, et al. (18)F-fluoroethyl-l-thyrosine positron emission tomography to delineate tumor residuals after glioblastoma resection: A comparison with standard postoperative magnetic resonance imaging. World Neurosurg. 2016;89:420–426.
   PubMed Web of Science ®Google Scholar
• Buchmann N, Gempt J, Ryang YM, et al. Can early postoperative O-(2-(18F)Fluoroethyl)-l-tyrosine positron emission tomography after resection of glioblastoma predict the location of later tumor recurrence? World Neurosurg. 2019;121:e467–e74.
   PubMed Web of Science ®Google Scholar
• Muther M, Koch R, Weckesser M, et al. 5-aminolevulinic acid fluorescence-guided resection of 18F-FET-PET positive tumor beyond gadolinium enhancing tumor improves survival in glioblastoma. Neurosurgery. 2019;85:E1020–E9.
   PubMed Web of Science ®Google Scholar
• Geisler S, Stegmayr C, Niemitz N, et al. Treatment-related uptake of O-(2-(18)F-Fluoroethyl)-l-tyrosine and l-[Methyl-(3)H]-methionine after tumor resection in rat glioma models. J Nucl Med. 2019;60:1373–1379.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Langen K, Holy R, et al. Assessment of treatment response in patients with glioblastoma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012;53:1048–1057.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Kracht LW, Burghaus L, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006;33:516–524.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Kracht LW, Burghaus L, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging. 2010;9:40–46.
   PubMed Web of Science ®Google Scholar
• Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging. 2003;13:269–271.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Langen KJ. Amino acid PET - an imaging option to identify treatment response, posttherapeutic effects, and tumor recurrence? Front Neurol. 2016;7:120.
   PubMed Web of Science ®Google Scholar
• Jansen NL, Suchorska B, Schwarz SB, et al. [18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Mol Imaging. 2013;12:137–147.
   PubMed Web of Science ®Google Scholar
• Pöpperl G, Goldbrunner R, Gildehaus FJ, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005;32:1018–1025.
   PubMed Web of Science ®Google Scholar
• Pöpperl G, Götz C, Rachinger W, et al. Serial O-(2-[(18)F]fluoroethyl)-L:-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006;33:792–800.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Ullrich R, Schroeter M, et al. Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. J Neurooncol. 2009;93:425–430.
   PubMed Web of Science ®Google Scholar
• Galldiks N, von Tempelhoff W, Kahraman D, et al. 11C-methionine positron emission tomographic imaging of biologic activity of a recurrent glioblastoma treated with stereotaxy-guided laser-induced interstitial thermotherapy. Mol Imaging. 2012;11:265–271.
   PubMed Web of Science ®Google Scholar
• Kristin Schmitz A, Sorg RV, Stoffels G, et al. Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine ((18)F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. Br J Neurosurg. 2019;13:1–7.
   PubMed Web of Science ®Google Scholar
• Ceccon G, Lazaridis L, Stoffels G, et al. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumor-treating fields: initial experience. Eur J Nucl Med Mol Imaging. 2018;45:1626–1635.
   PubMed Web of Science ®Google Scholar
• Bosnyak E, Barger GR, Michelhaugh SK, et al. Amino acid PET imaging of the early metabolic response during tumor-treating fields (ttfields) therapy in recurrent glioblastoma. Clin Nucl Med. 2018;43:176–179.
   PubMed Web of Science ®Google Scholar
• Tripathi M, Sharma R, Varshney R, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med. 2012;37:158–163.
   PubMed Web of Science ®Google Scholar
• Deuschl C, Kirchner J, Poeppel TD, et al. (11)C-MET PET/MRI for detection of recurrent glioma. Eur J Nucl Med Mol Imaging. 2018;45:593–601.
   PubMed Web of Science ®Google Scholar
• Hutterer M, Nowosielski M, Putzer D, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011;52:856–864.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Rapp M, Stoffels G, et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging. 2013;40:22–33.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Dunkl V, Ceccon G, et al. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. Eur J Nucl Med Mol Imaging. 2018;45:2377–2386.
   PubMed Web of Science ®Google Scholar
• Schwarzenberg J, Czernin J, Cloughesy TF, et al. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014;20:3550–3559.
   PubMed Web of Science ®Google Scholar
• Beppu T, Terasaki K, Sasaki T, et al. MRI and 11C-methyl-L-methionine PET differentiate bevacizumab true responders after initiating therapy for recurrent glioblastoma. Clin Nucl Med. 2016;41:852–857.
   PubMed Web of Science ®Google Scholar
• Deuschl C, Moenninghoff C, Goericke S, et al. Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study. Eur J Nucl Med Mol Imaging. 2017;44:1285–1295.
   PubMed Web of Science ®Google Scholar
• Lombardi G, De Salvo GL, Brandes AA, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20:110–119.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Werner J-M, Tscherpel C, et al. Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI. Neurooncol Adv. 2019 October 20. Epub ahead of print. DOI:10.1093/noajnl/vdz038
   Google Scholar
• Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol. 2009;95:87–93.
   PubMed Web of Science ®Google Scholar
• Roelcke U, Wyss MT, Nowosielski M, et al. Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro Oncol. 2016;18:744–751.
   PubMed Web of Science ®Google Scholar
• Voges J, Herholz K, Holzer T, et al. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg. 1997;69:129–135.
   PubMed Web of Science ®Google Scholar
• Würker M, Herholz K, Voges J, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med. 1996;23:583–586.
   PubMedGoogle Scholar
• Suchorska B, Unterrainer M, Biczok A, et al. (18)F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. J Neurooncol. 2018;139:721–730.
   PubMed Web of Science ®Google Scholar
• Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308:1881–1888.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Stoffels G, Ruge MI, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013;54:2046–2054.
   PubMed Web of Science ®Google Scholar
• Kebir S, Fimmers R, Galldiks N, et al. Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET. Clin Cancer Res. 2016;22:2190–2196.
   PubMed Web of Science ®Google Scholar
• Galldiks N, Dunkl V, Stoffels G, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015;42:685–695.
   PubMed Web of Science ®Google Scholar
• Karunanithi S, Sharma P, Kumar A, et al. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:1025–1035.
   PubMed Web of Science ®Google Scholar
• Rachinger W, Goetz C, Popperl G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505–511.
   PubMed Web of Science ®Google Scholar
• Maurer GD, Brucker DP, Stoffels G, et al. (18)F-FET PET imaging in differentiating glioma progression from treatment-related changes - a single-center experience. J Nucl Med. 2019 Sep 13 Epub ahead of print. DOI:10.2967/jnumed.119.234757.
   Google Scholar
• Bashir A, Mathilde Jacobsen S, Molby Henriksen O, et al. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). Neuro Oncol. 2019 Sep 6 Epub ahead of print. DOI:10.1093/neuonc/noz166.
   PubMedGoogle Scholar
• Youland RS, Pafundi DH, Brinkmann DH, et al. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol. 2018;137:583–591.
   PubMed Web of Science ®Google Scholar
• Xu W, Gao L, Shao A, et al. The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence. Oncotarget. 2017;8:91030–91039.
   PubMedGoogle Scholar
• Alkonyi B, Barger GR, Mittal S, et al. Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of alpha-11C-methyl-L-tryptophan PET. J Nucl Med. 2012;53:1058–1064.
   PubMed Web of Science ®Google Scholar
• Heinzel A, Muller D, Langen KJ, et al. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. J Nucl Med. 2013;54:1217–1222.
   PubMed Web of Science ®Google Scholar
• Baguet T, Verhoeven J, De Vos F, et al. Cost-effectiveness of [(18)F] Fluoroethyl-L-Tyrosine for temozolomide therapy assessment in patients with glioblastoma. Front Oncol. 2019;9:814.
   PubMed Web of Science ®Google Scholar
• Lohmann P, Werner JM, Shah NJ, et al. Combined amino acid positron emission tomography and advanced magnetic resonance imaging in glioma patients. Cancers (Basel). 2019;11:E153.
   PubMed Web of Science ®Google Scholar